Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Ferroptosis in inflammatory arthritis: A promising future.

Tytuł:
Ferroptosis in inflammatory arthritis: A promising future.
Autorzy:
Chang S; Department of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University, Changsha, China.
Tang M; Department of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University, Changsha, China.
Zhang B; Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, China.
Xiang D; Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, China.
Li F; Department of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University, Changsha, China.
Źródło:
Frontiers in immunology [Front Immunol] 2022 Jul 26; Vol. 13, pp. 955069. Date of Electronic Publication: 2022 Jul 26 (Print Publication: 2022).
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: [Lausanne : Frontiers Research Foundation]
MeSH Terms:
Arthritis, Rheumatoid*/drug therapy
Ferroptosis*
Iron Overload*
Animals ; Iron/metabolism ; Lipid Peroxidation
References:
Nat Commun. 2021 Jun 15;12(1):3644. (PMID: 34131139)
Inflamm Res. 2005 Jul;54(7):273-80. (PMID: 16134056)
Antioxidants (Basel). 2016 Feb 19;5(1):. (PMID: 26907355)
Arthritis Res Ther. 2006;8(6):R159. (PMID: 17042956)
Cell Rep. 2018 Jan 16;22(3):569-575. (PMID: 29346757)
Eur J Pharmacol. 2021 Nov 5;910:174500. (PMID: 34509462)
J Immunother Cancer. 2020 Nov;8(2):. (PMID: 33188036)
Arthritis Rheum. 2006 Jan;54(1):271-81. (PMID: 16385544)
Front Pharmacol. 2020 Mar 17;11:239. (PMID: 32256352)
Clin Exp Immunol. 2018 Jul;193(1):13-23. (PMID: 29315512)
Ann Rheum Dis. 1986 Oct;45(10):827-31. (PMID: 3789818)
Front Pharmacol. 2020 Jul 22;11:1061. (PMID: 32774303)
Exp Ther Med. 2021 Jan;21(1):72. (PMID: 33365072)
Medicine (Baltimore). 2016 Apr;95(14):e3150. (PMID: 27057839)
Cancers (Basel). 2020 Jan 09;12(1):. (PMID: 31936571)
Rheumatology (Oxford). 2022 Feb 08;:. (PMID: 35136972)
Nat Chem Biol. 2020 Mar;16(3):302-309. (PMID: 32080622)
J Immunol. 1994 Aug 15;153(4):1789-97. (PMID: 8046245)
Nat Chem Biol. 2017 Jan;13(1):91-98. (PMID: 27842070)
Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):E6806-E6812. (PMID: 27698118)
Med Sci Monit. 2018 May 31;24:3631-3636. (PMID: 29849019)
J Inflamm Res. 2021 Dec 18;14:6993-7006. (PMID: 34955646)
Signal Transduct Target Ther. 2021 Feb 3;6(1):49. (PMID: 33536413)
Biochem Biophys Res Commun. 2022 May 28;606:68-74. (PMID: 35339754)
Rheumatol Int. 2007 Oct;27(12):1131-4. (PMID: 17443328)
Redox Biol. 2017 Aug;12:558-570. (PMID: 28384611)
Immunol Res. 2021 Jun;69(3):225-238. (PMID: 33983569)
Redox Biol. 2017 Apr;11:254-262. (PMID: 28012440)
Front Cell Dev Biol. 2021 Jan 05;8:594509. (PMID: 33469535)
Oncotarget. 2016 Jun 14;7(24):36021-36033. (PMID: 27074570)
BMC Musculoskelet Disord. 2014 Jan 08;15:8. (PMID: 24401005)
Am J Physiol Cell Physiol. 2002 Dec;283(6):C1722-8. (PMID: 12388055)
Biomed Pharmacother. 2018 Jul;103:1585-1591. (PMID: 29864946)
Nat Commun. 2022 Feb 3;13(1):676. (PMID: 35115492)
J Cell Physiol. 2019 Jul;234(7):10123-10137. (PMID: 30387158)
Nat Rev Mol Cell Biol. 2021 Apr;22(4):266-282. (PMID: 33495651)
Ann Rheum Dis. 2002 Aug;61(8):741-4. (PMID: 12117685)
Anticancer Drugs. 2020 Jan;31(1):27-34. (PMID: 31490283)
Nat Cell Biol. 2019 May;21(5):579-591. (PMID: 30962574)
Cell Res. 2021 Feb;31(2):107-125. (PMID: 33268902)
Mol Cell. 2015 Jul 16;59(2):298-308. (PMID: 26166707)
Biochem Biophys Res Commun. 2019 Mar 5;510(2):278-283. (PMID: 30686534)
Med Sci Monit. 2004 Apr;10(4):BR91-5. (PMID: 15039637)
Int J Rheum Dis. 2011 Oct;14(4):325-31. (PMID: 22004228)
J Leukoc Biol. 2014 Apr;95(4):563-74. (PMID: 24453275)
J Clin Pathol. 2015 Aug;68(8):592-600. (PMID: 25897098)
Ann Rheum Dis. 1968 Jan;27(1):49-54. (PMID: 5640842)
Cell Death Differ. 2016 Mar;23(3):369-79. (PMID: 26794443)
Leukemia. 2001 Oct;15(10):1633-40. (PMID: 11587223)
Front Pharmacol. 2022 Feb 21;13:839464. (PMID: 35264971)
Apoptosis. 2021 Apr;26(3-4):152-162. (PMID: 33713214)
Cell Death Dis. 2020 Sep 17;11(9):775. (PMID: 32943613)
J Orthop Translat. 2020 Dec 17;27:33-43. (PMID: 33376672)
Sci Adv. 2022 Feb 4;8(5):eabl8920. (PMID: 35108055)
Ann Rheum Dis. 1985 Mar;44(3):183-8. (PMID: 3977421)
Chem Biol Interact. 2018 Feb 1;281:121-136. (PMID: 29258867)
Curr Biol. 2020 Nov 2;30(21):R1292-R1297. (PMID: 33142092)
Folia Med (Plovdiv). 2018 Mar 1;60(1):124-132. (PMID: 29668445)
Ann N Y Acad Sci. 2019 Dec;1457(1):166-178. (PMID: 31475364)
Inflammation. 2021 Feb;44(1):35-47. (PMID: 32920707)
Biomed Res Int. 2016;2016:6097417. (PMID: 27340664)
Mol Cell Proteomics. 2012 Feb;11(2):M111.013904. (PMID: 21997733)
Inflamm Res. 2017 Aug;66(8):637-651. (PMID: 28447122)
Redox Biol. 2015 Dec;6:472-485. (PMID: 26432659)
Arthritis Res Ther. 2018 Aug 15;20(1):179. (PMID: 30111358)
Cell Rep. 2017 Aug 15;20(7):1692-1704. (PMID: 28813679)
Hematology. 2020 Dec;25(1):108-111. (PMID: 32114962)
Int J Mol Sci. 2016 Jan 14;17(1):. (PMID: 26784172)
Cells. 2020 Jun 20;9(6):. (PMID: 32575749)
Antioxidants (Basel). 2021 Jan 02;10(1):. (PMID: 33401700)
Panminerva Med. 2003 Mar;45(1):7-13. (PMID: 12682616)
Mol Cell. 2019 Jan 17;73(2):354-363.e3. (PMID: 30581146)
Nature. 2015 Apr 2;520(7545):57-62. (PMID: 25799988)
Lancet. 1987 Feb 14;1(8529):391. (PMID: 2880200)
Biology (Basel). 2021 Sep 27;10(10):. (PMID: 34681066)
Cell Death Dis. 2020 Feb 3;11(2):88. (PMID: 32015325)
Biochem Biophys Res Commun. 2022 Apr 30;602:149-155. (PMID: 35276555)
Biomed Res Int. 2020 Sep 23;2020:4918239. (PMID: 33029510)
Biomaterials. 2020 Feb;232:119730. (PMID: 31918224)
Arthritis Res Ther. 2008;10(5):R107. (PMID: 18782442)
Aging (Albany NY). 2021 Feb 25;13(4):6182-6193. (PMID: 33632938)
Front Med (Lausanne). 2020 Nov 26;7:581402. (PMID: 33324661)
Cytokine. 2020 Apr;128:155002. (PMID: 31986444)
Oncotarget. 2016 Aug 9;7(32):50864-50874. (PMID: 27472463)
Nat Rev Rheumatol. 2016 Jul;12(7):385-97. (PMID: 27225300)
Cell Death Differ. 2022 May;29(5):895-910. (PMID: 35087226)
Cell. 2012 May 25;149(5):1060-72. (PMID: 22632970)
Nat Immunol. 2021 Sep;22(9):1107-1117. (PMID: 34385713)
Asian Pac J Trop Biomed. 2012 Feb;2(2):128-33. (PMID: 23569882)
Nutrients. 2018 Feb 09;10(2):. (PMID: 29425155)
Front Pharmacol. 2014 Jun 13;5:124. (PMID: 24982634)
Contributed Indexing:
Keywords: cell death; ferroptosis; inflammatory arthritis; iron accumulation; lipid peroxidation
Substance Nomenclature:
E1UOL152H7 (Iron)
Entry Date(s):
Date Created: 20220812 Date Completed: 20220815 Latest Revision: 20220825
Update Code:
20240104
PubMed Central ID:
PMC9361863
DOI:
10.3389/fimmu.2022.955069
PMID:
35958605
Czasopismo naukowe
Ferroptosis is a kind of regulatory cell death (RCD) caused by iron accumulation and lipid peroxidation, which is characterized by mitochondrial morphological changes and has a complex regulatory network. Ferroptosis has been gradually emphasized in the pathogenesis of inflammatory arthritis. In this review, we summarized the relevant research on ferroptosis in various inflammatory arthritis including rheumatoid arthritis (RA), osteoarthritis, gout arthritis, and ankylosing spondylitis, and focused on the relationship between RA and ferroptosis. In patients with RA and animal models of RA, there was evidence of iron overload and lipid peroxidation, as well as mitochondrial dysfunction that may be associated with ferroptosis. Ferroptosis inducers have shown good application prospects in tumor therapy, and some anti-rheumatic drugs such as methotrexate and sulfasalazine have been shown to have ferroptosis modulating effects. These phenomena suggest that the role of ferroptosis in the pathogenesis of inflammatory arthritis will be worth further study. The development of therapeutic strategies targeting ferroptosis for patients with inflammatory arthritis may be a promising future.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2022 Chang, Tang, Zhang, Xiang and Li.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies